• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

LDK378

Product ID L1340
Cas No. 1032900-25-6
Purity ≥99%
Product Unit SizeCostQuantityStock
1 mg $54.50 In stock
5 mg $102.10 In stock
25 mg $269.80 Please Inquire
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

LDK-378 is an anaplastic lymphoma kinase (ALK) inhibitor that displays anticancer chemotherapeutic activity. LDK-378 is used to treat ALK-positive non-small cell lung cancer (NSCLC), particularly in subjects experiencing resistance to crizotanib. This compound also inhibits IGF-1R.

Product Info

Cas No.

1032900-25-6

Purity

≥99%

Formula

C28H36ClN5O3S

Formula Wt.

558.13

IUPAC Name

5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine

Synonym

LDK-378, Ceritinib

Solubility

DMSO 20 mg/mL warmed (35.83 mM) Ethanol 3 mg/mL (5.37 mM) Water Insoluble

Appearance

off-white powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

L1340 MSDS PDF

Info Sheet

L1340 Info Sheet PDF

References

Iams WT, Lovly CM. Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer. Cancer J. 2015 Sep-Oct;21(5):378-82. PMID: 26389762.

Nishio M, Murakami H, Horiike A, et al. Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors. J Thorac Oncol. 2015 Jul;10(7):1058-66. PMID: 26010125.

Marsilje TH, Pei W, Chen B, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56(14):5675-90. PMID: 23742252.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only